Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Articles
Articles
Zanubrutinib Superior to Ibrutinib in Patients with Relapsed or Refractory CLL/SLL
By
Phoebe Starr
ASH Highlights
,
Leukemia
,
Lymphoma
February 2023, Vol 14, No 1
A head-to-head phase 3 clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) has found that zanubrutinib (Brukinsa), a next-generation Bruton tyrosine kinase (BTK) inhibitor, is more effective at preventing disease progression and better tolerated than ibrutinib (Imbruvica), a first-generation BTK inhibitor that has been the current standard of care for this population of patients.
Read More
GC012F, an Autologous BCMA and CD19 Dual-Targeting CAR T-Cell Therapy, as First-Line Treatment for Transplant-Eligible Patients with Newly Diagnosed High-Risk Multiple Myeloma
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
A phase 1 trial of GC012F demonstrated an overall response rate of 100% in high-risk, transplant-eligible patients with newly diagnosed multiple myeloma.
Read More
Subgroup Analysis of CANDOR-Evaluated Outcomes with Carfilzomib plus Dexamethasone and Daratumumab Based on Cytogenetic Risk
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
Data from a subgroup analysis of CANDOR supported the efficacy of daratumumab plus carfilzomib and dexamethasone in RRMM, even in high-risk patients.
Read More
First Results from a Phase 1 Study of BMS-986393, a GPRC5D-Targeted CAR T-Cell Therapy, in Patients with RRMM
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
Preliminary data support the use of BMS-986393 in patients with RRMM despite prior BCMA-directed therapy.
Read More
Subcutaneous Isatuximab Administration by an On-Body Delivery System May Provide a More Convenient Option for Patients with RRMM
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
Updated results from a phase 1 trial of subcutaneous isatuximab via OBDS continue to demonstrate an excellent local tolerability with comparable efficacy.
Read More
Anti-CD38 Antibodies in the Treatment of RRMM: Considerations for Pharmacists
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
Implementation of a pharmacist on the healthcare team can have significant clinical and economic benefits.
Read More
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in High-Risk Multiple Myeloma Patients: Interim Analysis of the GMMG-CONCEPT Trial
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
In the first trial with this treatment regimen, quadruplet induction with Isa-KRd in patients with high-risk MM demonstrated promising activity and a tolerable safety profile.
Read More
Evaluating Maintenance Treatments in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
Meta-analysis suggests that lenalidomide-carfilzomib may be the most effective maintenance treatment in patients with newly diagnosed multiple myeloma.
Read More
Iberdomide, a Cereblon E3 Ligase Modulator, plus Dexamethasone Demonstrated Activity in Heavily Pretreated Patients with Multiple Myeloma
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
Novel agent iberdomide demonstrated clinically meaningful activity and was generally well tolerated in a multicohort phase 1/2 trial.
Read More
Once-Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma: The SKylaRk Trial
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
A phase 2 study of isatuximab added to weekly carfilzomib, lenalidomide, and dexamethasone demonstrated promising efficacy and safety in transplant-eligible patients with newly diagnosed multiple myeloma.
Read More
Page 11 of 339
8
9
10
11
12
13
14
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Addressing Cancer Health Disparities: The No One Left Alone Initiative
Rohan Nathwani
,
Arva Patel
,
Warner Kornberg
,
Asutosh Gor, MD
,
Sashi Naidu, MD
,
Viral Rabara, MD
,
Niyati Nathwani, MD
,
Kashyap Patel, MD
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma